● Merck’s first Microbiology Application and Training Lab in India
● Supports capability built-up in microbial quality control in Pharma, and biopharma industry Merck invests €200,000 in the infrastructure of the new lab at Jigani
India, July 21 2022 – Merck, a leading science and technology company, today announced the opening of its first Microbiology Application and Training (MAT) Lab in Jigani, Bengaluru, offering facilities and technical expertise to support the India life science community on microbial quality control capability development.
Veena Panicker, Head of BioMonitoring, Merck Life Science in India, said, “According to IBEF, the Indian biotechnology industry was valued at US$ 70.2 billion in 2020 and is expected to reach US$ 150 billion by 2025. Merck’s MAT lab will be a space for pharma and biopharma companies to collaborate and enhance their capability in microbiology analysis.”
“Merck is a global leader with proven track record in technical expertise, training, method development and feasibility trials. Partnering with our customers, we can support them in product demonstrations, hands-on training, formal bioprocessing educational courses and experiments, as well as apply best practices and new approaches to develop, optimize and scale-up processes and simplify global technology transfer,” Veena added.
With an investment of €200,000, the MAT Centre spans an area size of 1,100 sqft. The testing services offered in the Lab includes sterility testing, rapid bioburden testing, pyrogen Testing, advance Membrane filtration and other pharma QC microbiology applications. The MAT Lab includes a vibrant space for certified training, application support, feasibilities studies and method development for Pharma and Biopharma industries.
In the global pharmaceuticals sector, India is a significant and rising player. India is the world’s largest supplier of generic medications, accounting for 20% of the worldwide supply by volume and supplying about 60% of the global vaccination demand**,” said Sreenath NS, Country Speaker, Merck India and Managing Director, Merck Life Science. The newly launched MAT Lab is a space that enables pharmaceutical and biopharmaceutical manufacturers to work side-by-side with our global microbiology and application experts to solve critical process developments and production challenges.”
The Lab offers customizable solutions and services that help pharmaceutical and biopharma companies as well as regulatory to improve their processes from drug discovery, development to manufacturing.
Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 60,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck generated sales of € 19.7 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.